More than 20 leading pharmaceutical, medical device, and diagnostic companies, along with major academic brain research centers and patient advocacy groups, have joined to form a new trade association called the Neurotechnology Industry Organization (NIO). Based in San Francisco, NIO is a nonprofit group created to accelerate the development of treatments and cures for central nervous system diseases.
“Despite the clear need and significant market opportunity, neurotechnology companies face a host of issues that stifle innovation, growth, and rapid delivery of effective therapies,” says Zack Lynch, founder and executive director of NIO. “NIO will provide a collective voice for commercial neuroscience organizations to address these issues.”
Founding member organizations include: Acumen Pharmaceuticals, Amarin, Brain Resource, Ceregene, Cyberkinetics Neurotechnology Systems, NeuroPace, NeuroNova, Sound Pharmaceuticals, Targacept, and United Therapeutics.